A new Phase 3 clinical research study is now open at OSF HealthCare Cancer Institute for adults with small cell lung cancer that has come back or stopped responding to prior treatment. The study is evaluating an investigational targeted therapy, ABBV-706, compared with current standard treatment options.

This study is testing a new kind of targeted medicine for people with relapsed or refractory small cell lung cancer. The investigational drug uses an antibody to locate cancer cells with the SEZ6 protein on their surface and then delivers treatment directly to those cells. Small cell lung cancer is an aggressive disease, and many patients need additional options after initial treatment stops working.

ABBV-706 (ClinicalTrials.gov Identifier: NCT07365241) is a global, randomized, open-label Phase 3 trial. The investigational medicine is an antibody-drug conjugate designed to find cancer cells that express a protein called SEZ6 and then deliver an anti-cancer agent directly to those cells. Participants are assigned to receive either ABBV-706 or a standard-of-care therapy, which may include topotecan, lurbinectedin, or amrubicin. Researchers are studying the safety of the investigational therapy and whether it can help control the cancer compared with current options. At OSF HealthCare, the study is being led by Principal Investigator Jun Zhang, MD, PhD, with Clinical Research Coordinator Jennifer Dixon.

This research is meaningful for patients and our community because relapsed small cell lung cancer remains very difficult to treat, and available options are limited. Studies like this help evaluate new targeted approaches under careful medical supervision and bring investigational therapies closer to those who need them most. Support for clinical research through OSF HealthCare allows us to offer hope and help advance care for future generations.

“At OSF HealthCare Cancer Institute, we are excited to participate in this important Phase 3 study, which brings a novel targeted therapy approach to patients in our region facing relapsed small cell lung cancer,” said Jun Zhang, MD, PhD, Principal Investigator. “Clinical research like this provides eligible patients the opportunity to explore promising new treatment approaches while helping to advance care for the broader community.”

All treatment approaches in this study are being evaluated for research purposes in accordance with the approved study protocol.

All clinical research conducted at OSF HealthCare undergoes rigorous review and ongoing oversight to help ensure patient safety and ethical conduct.

Patients interested in learning more about clinical research at OSF HealthCare are encouraged to speak with their care team, call (844) 673-4467 or Email: sfmc.clinicaltrials@osfhealthcare.org